Publication of the Day
Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study
The Lancet Infectious Disease, September 9, 2021
- This study compared SARS-CoV-2 IgG positivity between the CoronaVac and Pfizer (BNT162b2) vaccines using a dynamic national monitoring strategy.
- SARS-CoV-2 IgG positivity during week 4 after the first dose of CoronaVac was 28·1% (220 of 783 individuals), reaching a peak of 77·4% (1473 of 1902 individuals) during week 3 after the second dose.
- SARS-CoV-2 IgG positivity during week 4 after the first dose of the BNT162b2 vaccine was 79·4% (367 of 462 individuals), increasing to 96·5% (497 of 515 individuals) during week 3 after the second dose and remaining above 92% until the end of the study.
- IgG seropositivity was significantly lower in men than women and in people with diabetes or chronic diseases for CoronaVac vaccine recipients, and for individuals aged 60 years and older compared with people aged 18–39 years for both vaccines, 3–16 weeks after the second dose.
- IgG seropositivity was lower after CoronaVac than after BNT162b2 and declined over time since vaccination for CoronaVac recipients but not BNT162b2 recipients.
Publications
- A year of genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded in Africa
Science, September 9, 2021 - Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2
Science Immunology, September 2, 2021 - New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 2021
CDC, August 27, 2021 - Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
The Lancet, September 1, 2021 - Profiling CD8+ T Cell Epitopes of COVID-19 Convalescents Reveals Reduced Cellular Immune Responses to SARS-CoV-2 Variants
Cell Reports, August 26, 2021 - Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study
The Lancet, August 27, 2021 - Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
NEJM, August 25, 2021 - mRNA Vaccination Induces Durable Immune Memory to SARS-CoV-2 with Continued Evolution to Variants of Concern
BioRxiv, August 23, 2021 - A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope
Cell, August 18, 2021
- The Origins of SARS-CoV-2: A Critical Review
Cell, August 18, 2021
News
- 1 in every 500 US residents have died of Covid-19
CNN, September 15, 2021 - FDA staff say Pfizer COVID-19 boosters improve immunity but may not be needed
Reuters, September 15, 2021 - A Pfizer Analysis Makes The Case For A COVID Vaccine Booster
NPR, September 15, 2021 - Vaccination rate slowing in Czech Republic as infections rise
Euronews, September 15, 2021 - Covid-19 in Syria: Idlib faces wave of Delta variant infections
France24, September 15, 2021 - British government to start booster shots for 30 million people next week
Washington Post, September 14, 2021 - China rushes to contain ‘school centered’ Delta outbreak before major holiday season
CNN, September 14, 2021 - Only 2% of Covid-19 vaccines have been administered in Africa
UN News, September 14, 2021 - Biden to call on world leaders to commit to vaccinating 70% of world by next year
CNN, September 14, 2021 - Ardern extends Auckland lockdown as New Zealand battles Delta variant
France24, September 13, 2021 - 3 states have fully vaccinated more than 2/3 of residents. Elsewhere, hospitals are overwhelmed with unvaccinated Covid-19 patients (US)
CNN, September 13, 2021 - COVID-19: Fully vaccinated people made up just 1% of coronavirus deaths in England in first half of 2021, figures show
Sky News, September 13, 2021 - Gottlieb says vaccines could be approved for kids 5-11 by end of October (US)
CBS News, September 13, 2021